Intraperitoneal (IP) dose administration is the preferred method of dosing in the treatment of certain cancers as well as for peritonitis. Unfortunately, replicating IP administration in dogs in order to evaluate drug toxicity has posed multiple, serious challenges, rendering the approach unworkable in the laboratory. It is possible, however, to overcome these challenges by using a modified catheter with an access port to administer the investigational product. Frontage Labs has successfully applied this technique in dosing dogs as part of a study of a chemotherapy drug for ovarian cancer, demonstrating the viability of this method.

A number of the abuse-deterrent formulations in development and available on the market utilize hard-to-crush tablet technologies. Frontage possesses wide experience in running studies with controlled substances. Frontage provided full support in developing the protocol, revising study methodology, developing full package for IRB submission, including Informed Consent Form.

In this study, we developed and validated a LC-MS/MS method for the determination of Fluticasone propionate and Fluticasone 17β-carboxylic acid propionate (Fluticasone metabolite) in human K3EDTA plasma using Fluticasone propionate-d5 and Fluticasone 17β-carboxylic acid propionate-d3 as the internal standards (IS) using positive and negative TIS switch during analysis